CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017--
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will participate in a webcast discussion at the Goldman Sachs 38th Annual
Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June
13 at 4 p.m. PT.
Live audio webcast will be available under the Investors and Media
section of Seres’ website. A replay of the presentation will become
available approximately one hour after the event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics is a leading microbiome therapeutics platform company
developing a novel class of biological drugs that are designed to treat
disease by restoring the function of a dysbiotic microbiome, where the
natural state of bacterial diversity and function is imbalanced. The
company is planning to initiate the ECOSPOR III clinical study with its
lead program, SER-109, in patients with multiply recurrent C.
difficile infection. Seres’ second clinical candidate, SER-287, is
being evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis. Seres is also developing SER-262, the first ever
synthetic microbiome therapeutic candidate, in a Phase 1b study in
patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606006175/en/
Source: Seres Therapeutics, Inc.
IR and PR Contact:
Seres Therapeutics
Carlo Tanzi,
Ph.D., 617-203-3467
Head of Investor Relations and Corporate
Communications
Ctanzi@serestherapeutics.com
